Literature DB >> 19257803

Validation of serum markers for blood-brain barrier disruption in traumatic brain injury.

Brian J Blyth1, Arash Farhavar, Christopher Gee, Brendan Hawthorn, Hua He, Akshata Nayak, Veit Stöcklein, Jeffrey J Bazarian.   

Abstract

The blood-brain barrier (BBB), which prevents the entry into the central nervous system (CNS) of most water-soluble molecules over 500 Da, is often disrupted after trauma. Post-traumatic BBB disruption may have important implications for prognosis and therapy. Assessment of BBB status is not routine in clinical practice because available techniques are invasive. The gold-standard measure, the cerebrospinal fluide (CSF)-serum albumin quotient (Q(A)), requires the measurement of albumin in CSF and serum collected contemporaneously. Accurate, less invasive techniques are necessary. The objective of this study was to evaluate the relationship between Q(A) and serum concentrations of monomeric transthyretin (TTR) or S100B. Nine subjects with severe traumatic brain injury (TBI; Glasgow Coma Scale [GCS] score < or =8) and 11 subjects with non-traumatic headache who had CSF collected by ventriculostomy or lumbar puncture (LP) were enrolled. Serum and CSF were collected at the time of LP for headache subjects and at 12, 24, and 48 h after ventriculostomy for TBI subjects. The Q(A) was calculated for all time points at which paired CSF and serum samples were available. Serum S100B and TTR levels were also measured. Pearson's correlation coefficient and area under the receiver operating characteristic (ROC) curve were used to determine the relationship between the serum proteins and QA. Seven TBI subjects had abnormal Q(A)'s indicating BBB dysfunction. The remaining TBI and control subjects had normal BBB function. No significant relationship between TTR and QA was found. A statistically significant linear correlation between serum S100B and Q(A) was present (r = 0.432, p = 0.02). ROC analysis demonstrated a significant relationship between Q(A) and serum S100B concentrations at 12 h after TBI (AUC = 0.800; SE 0.147, 95% CI 0.511-1.089). Using an S100B concentration cutoff of 0.027 ng=ml, specificity for abnormal Q(A) was 90% or higher at each time point. We conclude that serum S100B concentrations accurately indicate BBB dysfunction at 12 h after TBI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19257803      PMCID: PMC2822805          DOI: 10.1089/neu.2008.0738

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  58 in total

Review 1.  Delivery of peptides and proteins through the blood-brain barrier.

Authors:  U Bickel; T Yoshikawa; W M Pardridge
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

Review 2.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

Authors:  H Reiber; J B Peter
Journal:  J Neurol Sci       Date:  2001-03-01       Impact factor: 3.181

3.  Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources.

Authors:  R E Anderson; L O Hansson; O Nilsson; J Liska; G Settergren; J Vaage
Journal:  Ann Thorac Surg       Date:  2001-05       Impact factor: 4.330

4.  Boxing and running lead to a rise in serum levels of S-100B protein.

Authors:  M Otto; S Holthusen; E Bahn; N Söhnchen; J Wiltfang; R Geese; A Fischer; C D Reimers
Journal:  Int J Sports Med       Date:  2000-11       Impact factor: 3.118

5.  IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function.

Authors:  E Csuka; M C Morganti-Kossmann; P M Lenzlinger; H Joller; O Trentz; T Kossmann
Journal:  J Neuroimmunol       Date:  1999-11-15       Impact factor: 3.478

Review 6.  Traumatic axonal injury: practical issues for diagnosis in medicolegal cases.

Authors:  J F Geddes; H L Whitwell; D I Graham
Journal:  Neuropathol Appl Neurobiol       Date:  2000-04       Impact factor: 8.090

7.  S100B expression in and effects on microglia.

Authors:  C Adami; G Sorci; E Blasi; A L Agneletti; F Bistoni; R Donato
Journal:  Glia       Date:  2001-02       Impact factor: 7.452

8.  Differential release of interleukines 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury.

Authors:  B Maier; K Schwerdtfeger; A Mautes; M Holanda; M Müller; W I Steudel; I Marzi
Journal:  Shock       Date:  2001-06       Impact factor: 3.454

9.  High serum S100B levels for trauma patients without head injuries.

Authors:  R E Anderson; L O Hansson; O Nilsson; R Dijlai-Merzoug; G Settergren
Journal:  Neurosurgery       Date:  2001-06       Impact factor: 4.654

10.  The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury.

Authors:  Kevin J Anderson; Stephen W Scheff; Kelly M Miller; Kelly N Roberts; Lesley K Gilmer; Cui Yang; Gerry Shaw
Journal:  J Neurotrauma       Date:  2008-09       Impact factor: 5.269

View more
  83 in total

1.  S100B blood levels and childhood trauma in adolescent inpatients.

Authors:  Tatiana Falcone; Damir Janigro; Rachel Lovell; Barry Simon; Charles A Brown; Mariela Herrera; Aye Mu Myint; Amit Anand
Journal:  J Psychiatr Res       Date:  2014-12-25       Impact factor: 4.791

2.  Exploratory Investigation of Early Biomarkers for Chronic Fatigue in Prostate Cancer Patients Following Radiation Therapy.

Authors:  Li Rebekah Feng; Brian S Wolff; Nada Lukkahatai; Alexandra Espina; Leorey N Saligan
Journal:  Cancer Nurs       Date:  2017 May/Jun       Impact factor: 2.592

3.  Neuron-specific enolase, but not S100B or myelin basic protein, increases in peripheral blood corresponding to lesion volume after cortical impact in piglets.

Authors:  Beth A Costine; Patricia B Quebeda-Clerkin; Carter P Dodge; Brent T Harris; Simon C Hillier; Ann-Christine Duhaime
Journal:  J Neurotrauma       Date:  2012-09-27       Impact factor: 5.269

4.  Altered levels of plasma neuron-derived exosomes and their cargo proteins characterize acute and chronic mild traumatic brain injury.

Authors:  Edward J Goetzl; Fanny M Elahi; Maja Mustapic; Dimitrios Kapogiannis; Moira Pryhoda; Anah Gilmore; Kimberly A Gorgens; Bradley Davidson; Anne-Charlotte Granholm; Aurélie Ledreux
Journal:  FASEB J       Date:  2019-01-03       Impact factor: 5.191

5.  Protein biomarkers for traumatic and ischemic brain injury: from bench to bedside.

Authors:  Zhiqun Zhang; Stefania Mondello; Firas Kobeissy; Richard Rubenstein; Jackson Streeter; Ronald L Hayes; Kevin K W Wang
Journal:  Transl Stroke Res       Date:  2011-12-07       Impact factor: 6.829

6.  Depletion of bone marrow-derived macrophages perturbs the innate immune response to surgery and reduces postoperative memory dysfunction.

Authors:  Vincent Degos; Susana Vacas; Zhenying Han; Nico van Rooijen; Pierre Gressens; Hua Su; William L Young; Mervyn Maze
Journal:  Anesthesiology       Date:  2013-03       Impact factor: 7.892

7.  S100B inhibition reduces behavioral and pathologic changes in experimental traumatic brain injury.

Authors:  Shruti V Kabadi; Bogdan A Stoica; Danna B Zimmer; Lauriaselle Afanador; Kara B Duffy; David J Loane; Alan I Faden
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-08       Impact factor: 6.200

8.  Serum S100B: a potential biomarker for suicidality in adolescents?

Authors:  Tatiana Falcone; Vincent Fazio; Catherine Lee; Barry Simon; Kathleen Franco; Nicola Marchi; Damir Janigro
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

9.  The Passage of S100B from Brain to Blood Is Not Specifically Related to the Blood-Brain Barrier Integrity.

Authors:  Andrea Kleindienst; Christian Schmidt; Hans Parsch; Irene Emtmann; Yu Xu; Michael Buchfelder
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-07-08

10.  Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients.

Authors:  Shawn G Rhind; Naomi T Crnko; Andrew J Baker; Laurie J Morrison; Pang N Shek; Sandro Scarpelini; Sandro B Rizoli
Journal:  J Neuroinflammation       Date:  2010-01-18       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.